Scarica l'app Stockscreener
15.29
3.66%
0.54
Dopo l'orario di chiusura:
15.96
0.67
+4.38%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNDM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$14.75
Aprire:
$14.93
Volume 24 ore:
1.97M
Relative Volume:
0.93
Capitalizzazione di mercato:
$1.03B
Reddito:
$796.00M
Utile/perdita netta:
$-136.49M
Rapporto P/E:
-7.3158
EPS:
-2.09
Flusso di cassa netto:
$-64.24M
1 W Prestazione:
+3.17%
1M Prestazione:
+23.01%
6M Prestazione:
-11.41%
1 anno Prestazione:
-59.23%
Intervallo 1D:
$14.80
$15.53
Intervallo di 1 settimana:
$13.49
$15.53
Portata 52W:
$9.98
$38.28
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Nome
Tandem Diabetes Care Inc
Settore
Industria
Telefono
858-366-6900
Indirizzo
12400 HIGH BLUFF DRIVE, San Diego, CA
Confronta TNDM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
15.29 | 971.65M | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
127.63 | 231.95B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
97.78 | 142.60B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
369.25 | 141.45B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.04 | 123.83B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
72.65 | 43.07B | 5.69B | 1.41B | 577.90M | 6.9828 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-08 | Iniziato | Oppenheimer | Outperform |
| 2025-08-12 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-07-09 | Downgrade | Citigroup | Neutral → Sell |
| 2025-06-16 | Iniziato | Truist | Hold |
| 2025-04-10 | Iniziato | Mizuho | Neutral |
| 2025-03-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-10-04 | Iniziato | Goldman | Neutral |
| 2024-10-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Iniziato | Canaccord Genuity | Buy |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-04-29 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Aggiornamento | Stifel | Hold → Buy |
| 2023-08-04 | Downgrade | Citigroup | Buy → Neutral |
| 2023-05-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-15 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-08-09 | Downgrade | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Underweight |
| 2020-12-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Iniziato | Wells Fargo | Overweight |
| 2020-07-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-18 | Reiterato | Raymond James | Outperform |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-06 | Iniziato | Raymond James | Outperform |
| 2020-02-04 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Iniziato | Guggenheim | Buy |
| 2019-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2019-05-17 | Reiterato | BofA/Merrill | Neutral |
| 2019-05-13 | Iniziato | SVB Leerink | Outperform |
| 2019-03-08 | Iniziato | BMO Capital Markets | Outperform |
| 2019-03-05 | Reiterato | BofA/Merrill | Neutral |
| 2019-02-27 | Reiterato | Lake Street | Buy |
| 2018-11-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Reiterato | Dougherty & Company | Buy |
| 2018-09-26 | Reiterato | Piper Jaffray | Overweight |
Mostra tutto
Tandem Diabetes Care Inc Borsa (TNDM) Ultime notizie
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation – TNDM - Bluefield Daily Telegraph
Is Tandem Diabetes Care Inc. (TD5A) stock a top pick for value investorsTreasury Yields & AI Forecasted Stock Moves - newser.com
Can Tandem Diabetes Care Inc. stock hit analyst price targetsTrade Signal Summary & Safe Capital Allocation Plans - newser.com
Tandem Diabetes Care Stock (TNDM) Opinions on FDA Clearance and Legal Concerns - Quiver Quantitative
TNDM Investors Have Opportunity to Join Tandem Diabetes Care, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Tandem Diabetes Care Inc Stock Analysis and ForecastPrice-to-Earnings Ratio Insights & Watch These Before They Go Viral - earlytimes.in
Published on: 2025-10-15 23:13:55 - newser.com
Truist Securities Raises Tandem Diabetes Care (TNDM) Price Targe - GuruFocus
Is Tandem Diabetes Care Inc. stock a buy on dipsQuarterly Profit Report & Comprehensive Market Scan Insights - newser.com
Is Tandem Diabetes Care Inc. still worth holding after the dipTrade Volume Summary & AI Enhanced Trading Alerts - newser.com
Using R and stats models for Tandem Diabetes Care Inc. forecastingMarket Trend Review & Expert-Curated Trade Recommendations - newser.com
Combining machine learning predictions for Tandem Diabetes Care Inc.Treasury Yields & AI Powered Trade Plan Recommendations - newser.com
Can Tandem Diabetes Care Inc. stock deliver sustainable ROEQuarterly Portfolio Report & Precise Entry and Exit Recommendations - newser.com
Volume spikes in Tandem Diabetes Care Inc. stock – what they meanForecast Cut & Growth-Oriented Investment Plans - newser.com
Published on: 2025-10-14 21:22:50 - newser.com
Real time pattern detection on Tandem Diabetes Care Inc. stockGDP Growth & Weekly Market Pulse Alerts - newser.com
TNDM Investor News: If You Have Suffered Losses in Tandem - GlobeNewswire
Is this a good reentry point in Tandem Diabetes Care Inc.Risk Management & Weekly Setup with High ROI Potential - newser.com
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tandem Diabetes Care, Inc.TNDM - PR Newswire
Candlestick signals on Tandem Diabetes Care Inc. stock todayWeekly Volume Report & AI Forecast for Swing Trade Picks - newser.com
Tandem Diabetes Care Inc. stock momentum explainedDividend Hike & High Accuracy Investment Signals - newser.com
What indicators show strength in Tandem Diabetes Care Inc.Weekly Trend Summary & Comprehensive Market Scan Insights - newser.com
Weekly Investment Analysts’ Ratings Updates for Tandem Diabetes Care (TNDM) - Defense World
Will Tandem Diabetes Care Inc. (TD5A) stock keep raising dividendsJuly 2025 Recap & Safe Investment Capital Preservation Plans - newser.com
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - Eastern Progress
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors t - GuruFocus
Tandem Diabetes, agilon health, GoodRx, Neogen, and Fortrea Stocks Trade Down, What You Need To Know - Yahoo Finance
United States Wearable Injectors Market 2025 | Industry - openPR.com
Is Tandem Diabetes Care Inc. stock attractive after correction2025 Price Action Summary & Reliable Entry Point Trade Alerts - newser.com
Lobbying Update: $50,000 of TANDEM DIABETES CARE lobbying was just disclosed - Quiver Quantitative
Is Tandem Diabetes Care Inc. (TD5A) stock undervalued after correctionTrade Risk Summary & Community Trade Idea Sharing - newser.com
Should you hold or exit Tandem Diabetes Care Inc. nowJuly 2025 Short Interest & Breakout Confirmation Trade Signals - newser.com
Could Tandem Diabetes Care’s (TNDM) Risk Profile Shift After Device Malfunction and New FDA Clearance? - Sahm
Ongoing Securities Investigation into Tandem Diabetes Care, Inc. (TNDM)Contact Levi & Korsinsky - Newsfile
Tandem Diabetes Care Stock Soars 12.2% to Intraday High of $14.85 - Markets Mojo
Tandem Diabetes Care Experiences Revision in Stock Evaluation Amid Market Fluctuations - Markets Mojo
INVESTOR ALERT: Investigation of Tandem Diabetes Care, Inc. (TNDM) Announced by Holzer & Holzer, LLC - GlobeNewswire
TNDM: Citigroup Raises Price Target to $15, Maintains Neutral Ra - GuruFocus
Tandem Diabetes Care (TNDM): Assessing Valuation After Lyumjev Compatibility Expands Insulin Pump Options - Sahm
Tandem Diabetes Care Inc Azioni (TNDM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tandem Diabetes Care Inc Azioni (TNDM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Novara Mark David | EVP & CHIEF COMMERCIAL OFFICER |
Sep 15 '25 |
Option Exercise |
0.00 |
7,415 |
0 |
36,214 |
| Novara Mark David | EVP & CHIEF COMMERCIAL OFFICER |
Aug 15 '25 |
Option Exercise |
0.00 |
76 |
0 |
28,839 |
| Morrison Susan | EVP & Chief Admin. Officer |
Aug 15 '25 |
Option Exercise |
0.00 |
2,600 |
0 |
39,376 |
| Sheridan John F | PRESIDENT & CEO |
Aug 15 '25 |
Option Exercise |
0.00 |
11,453 |
0 |
115,001 |
| Carpenter Rick | Chief Technology Officer |
Aug 15 '25 |
Option Exercise |
0.00 |
2,335 |
0 |
22,824 |
| Vosseller Leigh | EVP & CHIEF FINANCIAL OFFICER |
Aug 15 '25 |
Option Exercise |
0.00 |
2,998 |
0 |
36,258 |
| Hansen Shannon Marie | EVP & Chief Legal Officer |
Aug 15 '25 |
Option Exercise |
0.00 |
3,065 |
0 |
19,102 |
| Gasser Elizabeth Anne | EVP, Chief Strategy Officer |
Aug 15 '25 |
Option Exercise |
0.00 |
2,600 |
0 |
1,795 |
| Sheridan John F | PRESIDENT & CEO |
Aug 11 '25 |
Buy |
10.23 |
10,000 |
102,318 |
106,327 |
| Vosseller Leigh | EVP & CHIEF FINANCIAL OFFICER |
Aug 08 '25 |
Buy |
10.89 |
13,720 |
149,404 |
25,580 |
1.23%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):